Baxter International Inc. (BAX)
| Market Cap | 14.24B +23.2% |
| Revenue (ttm) | 11.47B +5.4% |
| Net Income | -1.06B |
| EPS | -2.06 |
| Shares Out | 517.00M |
| PE Ratio | n/a |
| Forward PE | 13.09 |
| Dividend | $0.04 (0.15%) |
| Ex-Dividend Date | Aug 28, 2026 |
| Volume | 8,192,691 |
| Open | 26.93 |
| Previous Close | 27.01 |
| Day's Range | 26.56 - 27.88 |
| 52-Week Range | 15.73 - 30.00 |
| Beta | 0.60 |
| Analysts | Hold |
| Price Target | 28.13 (+2.11%) |
| Earnings Date | Jul 30, 2026 |
About BAX
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies;... [Read more]
Financial Performance
In 2025, Baxter International's revenue was $11.24 billion, an increase of 5.72% compared to the previous year's $10.64 billion. Losses were -$957.00 million, 47.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for BAX stock is "Hold." The 12-month stock price target is $28.13, which is an increase of 2.11% from the latest price.
News
Baxter announces cash tender offers
Baxter (BAX) International has commenced cash tender offers for the maximum principal amount of validly tendered notes set forth, such that the aggregate purchase price, not including accrued and unpa...
Baxter Announces Cash Tender Offers
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced that it has commenced cash tender offers (each, an “Offer” and collectively, the “Off...
Baxter price target raised to $28 from $24 at BofA
BofA analyst Travis Steed raised the firm’s price target on Baxter (BAX) to $28 from $24 and keeps a Neutral rating on the shares. With the multiple having expanded, the…
Baxter price target raised to $29 from $24 at TD Cowen
TD Cowen raised the firm’s price target on Baxter (BAX) to $29 from $24 and keeps a Hold rating on the shares. The firm said they posted a solid quarter…
Baxter price target raised to $27 from $20 at Deutsche Bank
Deutsche Bank analyst Pito Chickering raised the firm’s price target on Baxter (BAX) to $27 from $20 and keeps a Hold rating on the shares.
Baxter price target raised to $28 from $24 at Stifel
Stifel raised the firm’s price target on Baxter (BAX) to $28 from $24 and keeps a Hold rating on the shares.
Baxter upgraded to Neutral from Sell at Citi
Citi analyst Joanne Wuensch upgraded Baxter (BAX) to Neutral from Sell with a price target of $28, up from $17.
Baxter upgraded to Neutral from Sell at Citi
Citi upgraded Baxter (BAX) to Neutral from Sell with a price target of $28, up from $17. The company’s Q2 earnings beat represented a strong step in the right direction,…
Baxter International Earnings Call Transcript: Q2 2026
Second quarter results exceeded expectations with 5% organic revenue growth and strong free cash flow. Adjusted EPS guidance was raised due to a one-time tariff refund, while ongoing supply and macroeconomic risks are being closely monitored.
Baxter International Earnings release: Q2 2026
Baxter International released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Baxter International Slides: Q2 2026
Baxter International has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Baxter International Quarterly report: Q2 2026
Baxter International has published its Q2 2026 quarterly earnings report on July 30, 2026.
Baxter raises annual profit forecast on strong demand for IV solutions
Medical products maker Baxter International on Thursday raised its annual profit forecast and beat Wall Street estimates for quarterly results, banking on robust sales of its medical products such a...
Baxter Reports Second-Quarter 2026 Results
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2026. “Our second-quarter results exceeded expectation...
Baxter price target raised to $25 from $19 at UBS
UBS raised the firm’s price target on Baxter (BAX) to $25 from $19 and keeps a Neutral rating on the shares ,after assuming coverage of the name. Baxter “should be…
Baxter price target raised to $24 from $19 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Baxter (BAX) to $24 from $19 and keeps a Hold rating on the shares. The firm’s model has been updated…
Baxter price target raised to $24 from $20 at TD Cowen
TD Cowen analyst Joshua Jennings raised the firm’s price target on Baxter (BAX) to $24 from $20 and keeps a Hold rating on the shares. The firm updated its model…
Baxter price target raised to $21 from $19 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Baxter (BAX) to $21 from $19 and keeps a Neutral rating on the shares.
Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, ...
Baxter price target raised to $24 from $22 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Baxter (BAX) to $24 from $22 and keeps an Outperform rating on the shares. The firm’s Q2 preview for…
Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company's progress and r...
Baxter International Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a stabilization year with flat to low single-digit growth, operational improvements, and a focus on reducing leverage below 3x. Strategic priorities include continuous improvement, margin expansion, and flexible capital allocation as the business prepares for renewed growth next year.
Baxter downgraded to Sell from Neutral at Citi
Citi analyst Joanne Wuensch downgraded Baxter (BAX) to Sell from Neutral with a price target of $17, down from $19. The company faces a back-half weighted year and is searching…
Baxter International Transcript: Bank of America Global Healthcare Conference 2026
Management detailed ongoing cultural and operational transformation, emphasizing accountability, decentralized decision-making, and improved incentive alignment. Portfolio stabilization, margin expansion, and free cash flow improvement are key priorities, with capital allocation flexibility expected once leverage falls below 3x.